Peak Group: Subsidiary Obtains Drug Registration Certificate

Announcement from the Peak Group: Recently, the wholly-owned subsidiary Zhejiang Peak Pharmaceutical Co., Ltd. has received the approval and issuance of the Drug Registration Certificate for Metformin Empagliflozin Tablets by the National Medical Products Administration. Metformin Empagliflozin Tablets are a compound preparation composed of metformin hydrochloride and empagliflozin, mainly used for blood sugar control in type 2 diabetes patients.